Impaired fear extinction contributes to the persistence of post-traumatic stress disorder (PTSD), and can be utilized for the study of novel therapeutic agents. Glutamate plays an important role in the formation of traumatic memories, and in the pathophysiology and treatment of PTSD, highlighting several possible drug targets. Recent clinical studies demonstrate that infusion of ketamine, a glutamate NMDA receptor antagonist, rapidly and significantly reduces symptom severity in PTSD patients. In the present study, we examine the mechanisms underlying the actions of ketamine in a rodent model of fear conditioning, extinction, and renewal. Rats received ketamine or saline 24 h after fear conditioning and were then subjected to extinction-training on each of the following three days. Ketamine administration enhanced extinction on the second day of training (i.e., reduced freezing behavior to cue) and produced a long-lasting reduction in freezing on exposure to cue plus context 8 days later. Additionally, ketamine and extinction exposure increased levels of mTORC1 in the medial prefrontal cortex (mPFC), a region involved in the acquisition and retrieval of extinction, and infusion of the selective mTORC1 inhibitor rapamycin into the mPFC blocked the effects of ketamine on extinction. Ketamine plus extinction also increased cFos in the mPFC and administration of a glutamate-AMPA receptor antagonist blocked the effects of ketamine. These results support the hypothesis that ketamine produces long-lasting mTORC1/protein synthesis and activity dependent effects on neuronal circuits that enhance the expression of extinction and could represent a novel approach for the treatment of PTSD.
Introduction
Post-traumatic stress disorder (PTSD) is a chronic and debilitating disorder with a life-time prevalence of 7.8% in the general population and higher in trauma-exposed groups (Kessler et al., 2008) . PTSD is typically characterized as persistent re-experiencing of memories, avoidance of cues or situations that are reminiscent of the traumatic event, emotional numbing, and hyperarousal. PTSD symptoms, particularly those related to re-experiencing the traumatic event, may fall within the fear-conditioning paradigm of neurobiology. Alterations in fear conditioning and extinction learning are thought to play a role in the onset and maintenance of PTSD (Milad et al., 2007; Pitman et al., 2012) .
Significant progress has been made in understanding the neurobiological basis of fear (Johansen et al., 2011; Kessler et al., 2008) . Pavlovian fear conditioning is believed to take place at the convergence of neural circuits linking the amygdala, hippocampus and medial prefrontal cortex (mPFC) (Knapska et al., 2012; Milad et al., 2007; Pitman et al., 2012; Sierra-Mercado et al., 2011) . Fear conditioning and extinction represent basic forms of associative learning that are highly conserved across species (Johnson et al., 2012) . Trauma-exposed patients suffering from PTSD experience deficits in the extinction of learned fear associations when compared to those who do not develop PTSD (Holmes and Singewald, 2013; Lommen et al., 2013; Parsons and Ressler, 2013) . Therefore, animal models involving fear conditioning and extinction learning in rodents represent an ideal paradigm for preclinical assessments of PTSD and for identifying novel pharmacotherapies.
Antidepressants, particularly selective serotonin reuptake inhibitors, can reduce PTSD symptoms in humans (Zhang and Davidson, 2007) and fear in rodents (Karpova et al., 2011) when combined with extinction therapy. During extinction, repeated exposure to a cue previously associated with a fear-provoking event results in the gradual formation of a new memory that is thought to suppress fear expression by establishing an inhibitory memory (Orsini and Maren, 2012). However, currently available antidepressants have several limitations, including slow onset of action (weeks to months) and low rates of efficacy, with only a subset of patients showing complete remission of PTSD symptoms (Ursano et al., 2004) . These factors underscore the urgent need to develop new pharmacotherapies that enhance extinction and can provide a more persistent and rapid reduction in PTSD symptoms.
There is mounting evidence for a role of the excitatory neurotransmitter glutamate in stress responsiveness, the formation of traumatic memories, and the pathophysiology of PTSD, raising the possibility of identifying novel glutamatergic interventions for this disorder (Horn et al., 2016; Rasmussen, 2016; Riaza Bermudo-Soriano et al., 2012) . Notably, recent clinical studies demonstrate that infusion of ketamine, a Neurobiology of Disease 100 (2017) 1-8
